AI x Life Science
AI is transforming drug discovery, diagnostics, and medical devices—cutting timelines by years. But the law is struggling to keep up. Understanding the evolving IP landscape is critical for protecting your innovations.
New Development — December 2025
Director Squire's USPTO is taking a more favorable stance on AI and diagnostic patent eligibility. The recent In re Desjardins decision and new guidance memoranda create a window of opportunity for life science companies to secure broader patent protection.
Read the full analysis →Award-Winning Research
Recognized for "Emerging Legal Terrain: IP Risks from AI's Role in Drug Discovery" — one of only 20 articles selected from the nation's 1,000 largest law firms.
Key Legal Considerations
Patent protection requires significant human contribution to the invention—AI cannot be listed as an inventor under current law (Thaler v. Vidal).
The USPTO under Director Squire is signaling a more expansive view of patent eligibility for AI and diagnostics inventions—now is the time to file.
Proper documentation of human contributions vs. AI involvement is essential for patent applications and M&A due diligence.
Different Perspectives
Related Articles
Director Squire's USPTO is signaling a more favorable stance on AI and diagnostics patents. Life science companies should seize this moment to build robust IP portfolios before the window closes.
Healthcare AI faces unique governance challenges at the intersection of FDA regulations and patent law. Learn how to build compliant AI systems while protecting your diagnostic and therapeutic innovations.
Key mistakes life sciences companies make when developing AI governance frameworks, from patent inventorship complexities to inadequate documentation standards.
Understanding how patenting drugs discovered with AI assistance requires significant human contribution, and strategies for startups and big pharma to navigate these challenges.
Comprehensive guide on IP risks, licensing considerations, M&A due diligence, and documentation practices for companies using AI in drug discovery.
Diving into the Thaler v. Vidal decision and what it means for the future of life sciences and technology patents when AI assists in innovation.
Exploring considerations for companies large and small innovating in AI drug discovery, including ensuring human contribution and assessing third-party AI tools.
Exploring the legal implications of AI-driven drug discovery, including patent eligibility, inventorship challenges, and strategies for pharmaceutical companies to protect their innovations.
Analyzing the Cardionet decision and potential avenues to patent eligibility for diagnostic inventions involving improved devices or laboratory techniques.
I help pharmaceutical companies, biotech startups, and diagnostics companies develop IP strategies that protect AI-assisted discoveries while positioning for successful exits and partnerships.
Get in Touch